Table 1.
Baseline characteristics of study patients with SPIDDM
| Sitagliptin group (n = 6) | Pioglitazone group (n = 5) | p value | |
|---|---|---|---|
| Age (years) | 56 ± 16 | 57 ± 8 | 0.93 |
| Sex (male:female) | 2:4 | 2:3 | 0.85 |
| Duration of diabetes (years) | 4.3 ± 2.9 | 3.8 ± 4.1 | 0.81 |
| Metformin use before entry, n (%) | 5 (83) | 3 (60) | 0.48 |
| BMI (kg/m2) | 23.2 ± 6.2 | 23.9 ± 3.9 | 0.73 |
| HbA1c (%) | 7.5 ± 0.5 | 7.3 ± 0.4 | 0.59 |
| GADAb (U/ml) | 2.65 (1.6–250) | 8.4 (1.8–14,000) | 0.93 |
| IA-2Ab positive, n (%) | 2 (33) | 1 (20) | 0.70 |
| IAA positive, n (%) | 0 (0) | 0 (0) | na |
| TAb (TPOAb and/or TGAb) positive, n (%) | 2 (33) | 3 (60) | 0.46 |
Data are n (%), mean ± SD or median (range)
BMI body mass index, GADAb glutamic acid decarboxylase autoantibodies, IA-2Ab insulinoma-associated antigen-2 autoantibodies, IAA insulin autoantibodies, TAb thyroid autoantibodies, TPOAb thyroid peroxidase autoantibodies, TGAb thyroglobulin autoantibodies, na not applicable